CP-690550 --- JAK Inhibitor

Catalog No. size PriceQuantity
M60033-2S 2 mg solid $79
M60033-25S 25 mg solid $550


CP-690550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. It inhibits recombinant human JAK1 (IC50 ~ 3.2 nM), JAK2 (IC50 ~4.1 nM), and JAK3 (IC50 ~1.6 nM). In cellular assays CP-690550 showed potent effects in the IL-2 blast proliferation assay (IC50 ~11 nM, mediated via JAK1 and JAK3) and HU03 cellular specificity assay (IC50 ~324 nM, mediated via JAK2), but has relatively minimal effects on general cell growth (>10 µM activity in the HFF assay).

Product information

CAS Number: 477600-75-2

Molecular Weight: 312.37

Formula: C16H20N6O




Chemical Name: 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Smiles: CN([C@H]1CN(CC[C@H]1C)C(=O)CC#N)C1N=CN=C2NC=CC2=1


InChi: InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 100 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

CP-690550 was used at 0.05-1 µM concentration in a panel of in vitro assays.

In Vivo:

CP-690550 was orally dosed to rats at 10-50 mg/kg once or twice per day.


  1. Flanagan ME, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. (2010) J Med Chem. 53(24):8468-84
  2. Ghoreschi K, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). (2011) J Immunol. 186(7):4234-43.
  3. Ju W, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. (2011) Blood. 117(6):1938-46.

Products are for research use only. Not for human use.


Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed